CD4 and neuroblastoma: In this regard, it is noteworthy that the percentage of CD4+ T cells appeared to positively correlate with the clinical outcome in neuroblastoma patients treated with GD2-CAR specific T cells [8], and other protocols comprise the addition of unmodified CD4+ T cells to the infusates [27].